ALS Center – Neurology Departement

CHU Dupuytren

The ALS Center at CHU Dupuytren organizes high quality care for ALS patients, education for healthcare professionals and engages in clinical research activities.

Limoges_logo
CHU Dupuytren

Patients diagnosed with ALS receive a multidisciplinary evaluation every 3 months. In addition, we provide medical, social and home support. To share our expertise regarding care for ALS patients, we provide training sessions for medical and paramedical staff, and organise a symposium with other French ALS Centers. Our research interests include epidemiology, cognition and nutrition. To this extent, we establish internal and multicenter research protocols and collaborate with the pharmaceutical industry in therapeutic research.

 

Contact
Location
2 Avenue Martin Luther King, Limoges, France

Our Specialists

Philippe Couratier

Professor of Neurology

Professor Philippe Couratier is Neurologist in the University Hospital of Limoges. After […]

Philippe Couratier
Current trials
Active
Phase ii

DAZALS trial

Industry trial
In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS (also known as MND) to understand its safety (side effects) and to determine if dazucorilant can slow down the worsening of the disease. The effects of dazucorilant will be compared to the effects of a placebo. This study is sponsored by Corcept Therapeutics.
Read more
Active
Phase ii

CARDINALS

Industry trial
The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms. Researchers will also test the safety and tolerability of the study drug and how the body responds to it. The study drug is a liquid that is swallowed 2 times a day.
Read more
Completed
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Completed
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Completed
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more